Global Retinoblastoma Treatment Market Size To Exceed USD 3.8 Billion By 2033 | CAGR of 4.28%
Category: HealthcareGlobal Retinoblastoma Treatment Market Size To Exceed USD 3.8 Billion By 2033 | CAGR of 4.28%
According to a research report published by Spherical Insights & Consulting, the Global Retinoblastoma Treatment Market Size is to Grow from USD 2.5 Billion in 2023 to USD 3.8 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 4.28% during projected period.
Get more details on this report -
Browse key industry insights spread across 200 pages with 110 Market data tables and figures & charts from the report on the “Global Retinoblastoma Treatment Market Size, Share, and COVID-19 Impact Analysis, By Treatment Type (Surgery, Radiation Therapy, Laser Therapy, Cryotherapy, Chemotherapy, Bone Marrow Transplantation/Stem Cell Transplant and Targeted Therapies & Gene Therapy), By Type of Retinoblastoma (Non-Hereditary and Hereditary Retinoblastoma), By Type of Staging (Intraocular Retinoblastoma and Extraocular Retinoblastoma), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.” Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/retinoblastoma-treatment-market
Retinoblastoma is a disease in which malignant cancer cells form in the tissues of the retina. It is a pediatric cancer that requires careful integration of multidisciplinary care. The primary goal is to save the patient’s life and preserve useful vision. The six types of standard treatments used are cryotherapy, thermotherapy, chemotherapy, radiation therapy, high-dose chemotherapy with stem cell rescue, and surgery (enucleation). The oncolytic virus therapy includes the injection of oncolytic adenovirus into a tumor having anticancer effects in retinoblastoma. The advancement in targeted chemotherapy has improved the possibility of global salvage. The increasing trend to use various approaches like novel drugs, oncolytic viruses and immunotherapy in the treatment of retinoblastoma, access to advanced knowledge on tumor biology and the drug response, and development of new routes of drug delivery leads to effective therapies in retinoblastoma. The increasing prevalence of retinoblastoma with the rising development of novel drug candidates for treating retinoblastoma leads to drive the market growth. Further, the rising awareness about retinoblastoma and the increasing number of funding for developing healthcare infrastructure is also responsible for driving the global retinoblastoma treatment. On the contrary, the high cost of retinoblastoma treatment and the associated side effects of retinoblastoma therapy are restraining the global retinoblastoma treatment market.
The chemotherapy segment is anticipated to hold the largest market share during the forecast period.
Based on treatment type, the global retinoblastoma treatment market is segmented into surgery, radiation therapy, laser therapy, cryotherapy, chemotherapy, bone marrow transplantation/stem cell transplant, and targeted therapies & gene therapy. Among these, the chemotherapy segment is anticipated to hold the largest market share during the forecast period. Chemotherapy is the most well-known treatment of retinoblastoma, which helps children avoid surgery. The rising number of retinoblastoma cases and ongoing improvement in medication and chemotherapy regimes leads to drive the market demand in the chemotherapy segment.
The non-hereditary segment dominates the market with the largest revenue share through the forecast period.
Based on the type of retinoblastoma, the global retinoblastoma treatment market is segmented into non-hereditary and hereditary retinoblastoma. Among these, the non-hereditary segment dominates the market with the largest revenue share through the forecast period. Non-hereditary retinoblastoma causes tumors to grow in one or both eyes in children. Retinoblastoma instances are not usually inherited. The development of customized treatment plans especially created for non-hereditary type driving the market growth.
The intraocular retinoblastoma segment accounted for the largest revenue share in 2023.
Based on the type of staging, the global retinoblastoma treatment market is segmented into intraocular retinoblastoma and extraocular retinoblastoma. Among these, the intraocular retinoblastoma segment accounted for the largest revenue share in 2023. An internal tumor in the eye potentially affecting the retina as well as other areas of the eye, is known as intraocular retinoblastoma. It has a higher incidence rate as compared to extraocular. With the rising need for treatment, the intraocular segment market demand is expected to increase.
North America dominates the market with the largest market share over the forecast period.
Get more details on this report -
North America dominates the market with the largest market share over the forecast period. The increasing cases of retinoblastoma with its growing awareness in the region leads to drive the market demand. The developed medical technology and diagnostic tools allow accurate and early detection of retinoblastoma cases, leading to timely and effective treatment. The presence of leading research and development centers in pediatric oncology and advancement in the healthcare infrastructure fosters market growth in the region
Asia-Pacific region is expected to grow the fastest during the forecast period. The rising cases of retinoblastoma in the region are anticipated to drive the market demand for retinoblastoma treatment. Further, the ongoing efforts by the organization to improve healthcare infrastructure contribute to market growth. Additionally, the increasing awareness among the people regarding retinoblastoma and its treatments leads to drive the market in the region.
Major vendors in the global retinoblastoma treatment market are Bristol Myers Squibb Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Cellceutix Corporation, GlaxoSmithKline, Johnson and Johnson Services Inc., Novartis AG, Candila Pharmaceuticals, Merck & Co., Inc., AstraZeneca, Bayer AG, AbbVie Inc., Takeda Pharmaceutical Company Ltd., and Other Key Players.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Developments
- In October 2023, Novartis AG announced favorable Phase II research findings for IPI-545, indicating potential tolerance and effectiveness in the treatment of retinoblastoma.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global retinoblastoma treatment market based on the below-mentioned segments:
Global Retinoblastoma Treatment Market, Treatment Type Analysis
- Surgery
- Radiation Therapy
- Laser Therapy
- Cryotherapy
- Chemotherapy
- Bone Marrow Transplantation/Stem Cell Transplant
- Targeted Therapies & Gene Therapy
Global Retinoblastoma Treatment Market, Type of Retinoblastoma Analysis
- Non-Hereditary
- Hereditary Retinoblastoma
Global Retinoblastoma Treatment Market, Type of Staging Analysis
- Intraocular Retinoblastoma
- Extraocular Retinoblastoma
Global Retinoblastoma Treatment Market, Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Uk
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?